Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells.
Neural stem cells (NSCs) are currently considered very hopeful candidates for cell replacement therapy in neurodegenerative pathologies such as Parkinson's disease (PD), but like embryonic neural tissue transplantation, levodopa medication may still be required to improve symptoms even after cell transplantation. The issues of whether levodopa induces cytotoxicity and apoptosis of NSCs following transplantation, as well as the means to prevent these processes from occurring remain to be elucidated. In this study, the possible cytotoxicity of levodopa at different doses on C17.2 neural stem cells and subsequent neuroprotection by pergolide were investigated. The cell viability was determined by the MTT assay. Cell proliferation was assayed by BrdU labeling, while apoptosis was detected by Annexin-V-FLUOS staining and flow cytometry. Levels of p53, Bax, Bcl-2, NFkB, cytochrome c, caspase-3 as well as cleavage of caspase-3 were measured by western blotting. We found levodopa induced a concentration- and time-dependent decrease in cell viability and proliferation. Apoptotic cells were observed at different stages, specifically 12 and 24 h following exposure to levodopa (200 microM). Elevated p53, Bax, cytochrome c, caspase-3 and active fragments of caspase-3 protein were observed in the cells exposed to levodopa. These alterations were partly inhibited by pergolide, a dopamine receptor agonist, while Bcl-2 and NFkB p65 levels remained constant at the various time-points in all the groups examined. These observations indicate that levodopa at high concentrations (> or = 200 microM) was neurotoxic to C17.2 neural stem cells via inhibition of DNA synthesis and cell proliferation. Activation of the mitochondria-dependent pathway and caspase-3 protease may contribute to the mechanism by which levodopa induces apoptosis. Pergolide, an anti-Parkinson drug, has a neuroprotective effect and partly blocks levodopa-induced cytotoxicity.
Liu
Wei-Guo
WG
Department of Neurology, Clinical & Research Center for Parkinson Disease & Movement Disorders, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, PR China.
Chen
Yan
Y
Li
Biao
B
Lu
Guo-Qiang
GQ
Chen
Sheng-Di
SD
D000818:Animals; D017304:Annexin A5; D000963:Antimetabolites; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D001973:Bromodeoxyuridine; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D015259:Dopamine Agents / Q000633:toxicity*; D005434:Flow Cytometry; D016650:Fluorescein-5-isothiocyanate; D007980:Levodopa / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D051379:Mice; D009474:Neurons / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010479:Pergolide / Q000627:therapeutic use*; D013234:Stem Cells / Q000187:drug effects*; D013778:Tetrazolium Salts; D013844:Thiazoles
D017304:Annexin A5; D000963:Antimetabolites; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D013778:Tetrazolium Salts; D013844:Thiazoles; D010479:Pergolide; D007980:Levodopa; C022616:thiazolyl blue; D001973:Bromodeoxyuridine; D016650:Fluorescein-5-isothiocyanate